Search Results
Your search for Sarah A. Holstein, MD, PhD matches 6 pages
Showing 1 - 6Before Becoming a Leader in Multiple Myeloma Research, Sarah A. Holstein, MD, PhD, Considered a Career in Music
Myeloma expert Sarah A. Holstein, MD, PhD, was born and reared in Iowa City, a college town in eastern Iowa along the banks of the Iowa River. “The town itself is small, but it doubles in population when all the college students are present. Both my parents had a PhD in humanities, so I had no...
In All Candor, What Does CANDOR Bring to the Table in Relapsed or Refractory Multiple Myeloma?
An updated analysis of the phase III CANDOR study—recently reported by Usmani et al and summarized in this issue of The ASCO Post—confirmed a significant progression-free survival benefit for the combination of daratumumab, carfilzomib, and dexamethasone (KdD) over carfilzomib and dexamethasone...
Hematologic Oncology Highlights 2019–2020 Almanac
The past year has seen remarkable advances in the treatment of leukemia, lymphoma, and multiple myeloma, which combined account for 9.9% of the estimated 1,806,590 new cases of cancer diagnosed in the United States and an estimated 56,840 cancer-related deaths.1 Novel therapies are providing...
Sarah A. Holstein, MD, PhD, on Multiple Myeloma: Expert Perspective on Five Key ASCO20 Abstracts
Sarah A. Holstein, MD, PhD, of the University of Nebraska Medical Center, discusses top myeloma abstracts from the ASCO20 Virtual Scientific Program: the ENDURANCE trial on carfilzomib, lenalidomide, dexamethasone, and bortezomib; the STaMINA study on transplantation strategies; a first-in-human...
Evidence-Based Support for Triplet Therapies in Multiple Myeloma
Over the past 15 years, multiple myeloma has garnered among the highest number of regulatory approvals by the U.S. Food and Drug Administration (FDA) for the management of all phases of the disease. This fast-expanding repertoire of treatment options has pushed the median survival of multiple...
ASCO 2015: Phase III Study Confirms Benefits of Lenalidomide Maintenance Therapy for Patients With Multiple Myeloma
A large, cooperative group study directed by the Alliance for Clinical Trials in Oncology has confirmed previous evidence that the drug lenalidomide (Revlimid) delays time to disease progression for patients with multiple myeloma and is an important treatment option for patients with this rare but...
